Please login to the form below
Eklira
This page shows the latest Eklira news and features for those working in and with pharma, biotech and healthcare.
AZ adds to respiratory portfolio with Actavis drugs
It follows a similar deal agreed in July last year for AZ to buy the global respiratory portfolio of Almirall for $2bn, including the approved Eklira (aclidinium) for COPD and several
Latest news
-
AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio
Almirall's franchise includes Eklira (aclidinium), LAS40464 (a combination of aclidinium with formoterol, which has been filed in Europe), LAS100977 (abediterol), a once-daily phase II long-acting beta2-agonist (LABA),
-
Almirall expands in US via $400m deal to buy Aqua
under 22m on the back of high roll-out costs for new products such as Sativex (nabiximols) for spasticity in multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD) treatment Eklira
-
IQWiG knocks back Almirall's Eklira
A long-acting bronchodilator, Eklira is licensed to treat adults with chronic-obstructive pulmonary disease (COPD) and works by widening their narrowed airways. ... The cost effectiveness body was similarly scathing when it came to making indirect
-
Breathing easier
While there are several therapies currently in late-stage clinical trials for COPD — including aclidinium bromide (Eklira, Almirall Prodesfarma/Forest Laboratories), vilanterol/fluticasone furoate (Relovair, GSK), andolast (Rottapharm Madaus) and
-
Almirall posts positive results
Potential key growth drivers ahead include the Eklira franchise, linaclotide, which offers a pan-European first-in-class opportunity in late stage development, Sativex for which approval is expected in Q2,
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch table for November 2014
Eklira and Duaklir. Business unit acquisition. 3, 075. Pfizer / Merck KGaA.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Windrose Consulting Group
Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
